Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome)

• Status: Recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. Cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. Subacute cough has a 3~8 weeks course of disease. Its main etiology is postinfectious cough, which is mostly secondary to viral infection.The drug in this study is for post-infection cough in subacute cough. After long-term clinical practice, six traditional Chinese medicines, including Aster, Lonicera japonica, Shegan, dried ginger, mango seed and Schizonepeta tenuifolia, were selected to form Zihua Wenfei Zhisou Decoction. This product has the effect of relieving wind, relieving cough, warming the lung and resolving phlegm. It can be used for the cough syndrome caused by Wind-cold invading lungs syndrome. The aim is to evaluate the efficacy and safety of Zihua Wenfei Zhisou Granule in the treatment of postinfection cough (wind-cold lung syndrome) with placebo as a control.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: DoCare Pharmaceutial Technology Co.,Ltd

Criteria

Inclusion Criteria:

• When signing the informed consent form, the age is between 18 and 65 years old (including 18 and 65 years old)；

• Diagnosis of postinfectious cough;

• Wind-cold invading lungs syndrome in TCM Zheng;

• Baseline cough visual analogue scale of 60 mm or more;

• Cough duration of 3- 6 weeks;

• Voluntarily provide written and informed consent.

Exclusion Criteria:

• Cough caused by cough variant asthma, upper airway cough syndrome, eosinophilic bronchitis, gastroesophageal reflux cough or any other concomitant conditions;

• Patients with severe pulmonary diseases such as lung cancer, lung tuberculosis, or lung fibrosis;

• After inhaling bronchodilator, patients with FEV1/FVC<70% were excluded;

• Subjects who have taken angiotensin-converting-enzyme inhibitor (ACEI) in the past month;

• Current smokers or recent ex-smokers quitting smoking less than 3 months ago;

• FeNO ≥ 32 ppb or Bronchial provocation test positive (for FeNO and Bronchial provocation test, if the center cannot detect it, it can be detected in other qualified tertiary hospitals);

• Combined with serious cardio-cerebrovascular diseases, malignant tumors, diseases of blood and hematopoietic system, gastrointestinal diseases or other serious or progressive diseases of the system; Or those who are unable to cooperate or unwilling to cooperate due to severe mental illness, severe cognitive impairment, etc;

• Liver and kidney dysfunction: ALT or AST >2 times the upper limit of normal reference value; And/or serum creatinine >1.5 times the upper limit of normal reference value, or eGFR< 60 mL/min/1.73m2;

• White blood cell count < 3.0×109/L or > 10.0×109/L, and/or neutrophil granulocyte > 80%;

• Patients with temperature of 37.3℃ or above;

• Patients taking similar medications in the last one week;

• Have a long history of alcohol or drug abuse;

• Pregnancy or potential pregnancy or lactation;

• Allergic constitution or known to be allergic to any component in tested drug;

• Patients having participated or participating in another trial in last 3 month;

• Patients unsuitable for clinical trials judged by researchers.